



**XXVI Biennial Meeting of the
International Society for Eye Research**
20 - 24 October 2024 / Buenos Aires, Argentina



ISER 2024 PROGRAM ABSTRACTS

XXVI Biennial Meeting of the International Society for Eye Research
October 20 - 24, 2024 | Buenos Aires, Argentina

ORAL PRESENTATIONS	10
AI in Ophthalmology	10
Advances in optical coherence tomography.....	10
Artificial intelligence in ophthalmology.....	14
Artificial intelligence in the optic nerve.....	18
ChatGPT, generative AI & large language models in ophthalmology & healthcare.....	21
Cornea and Ocular Surface	23
Corneal endothelium.....	23
Corneal epithelial wound healing.....	26
Corneal nerves: the guardians of ocular surface health.....	30
Cutting-edge approaches to the study of the molecular mechanisms underlying ocular pain.....	34
Emerging methodologies and treatments for ocular surface pathologies.....	38
Molecular targets for cornea pathologies.....	43
New therapeutics and models in ocular surface research.....	47
Novel strategies for corneal repair- 3 is the magic number.....	50
Ocular chemical injury and medical countermeasures.....	55
Ocular surface inflammation and immunity.....	59
Proteostasis and ER stress in corneal pathologies.....	63
Role of extracellular matrix in ocular healing and clinical applications.....	67
Glaucoma	71
Animal models of glaucoma.....	71
Biomechanics of the sclera and optic nerve head.....	75
Glaucoma gene discovery and clinical translation.....	79
Insights into the Schlemm's canal biology.....	83
IOP and ICP rhythms and their diurnal regulation.....	87
Mitochondria and metabolism in glaucoma.....	92
Molecular and cellular mechanisms of outflow regulation.....	96
Molecular pathogenesis of glaucoma.....	100
Neuroinflammation in glaucoma.....	104
New therapeutic targets for retinal ganglion cell neuroprotection.....	108
Physiology and pathology of outflow pathways and potential therapeutic approaches for glaucoma.....	112
iPS Cells in Ophthalmology	117
iPSC-derived RPE to develop treatments for degenerative eye diseases.....	117
iPSC-derived RPE to develop treatments for degenerative eye diseases-1.....	121
New perspectives in the application of pluripotent stem cell technologies for studying retinal development and disease.....	125
Recent advances in stem cell based treatment paradigms for optic nerve degeneration.....	129
Retinal organoids: emergent technologies and applications.....	134
Using iPSCs to unravel the network of neurodegeneration.....	138
Using patient induced pluripotent stem cells to evaluate disease pathology and test novel therapeutics.....	142

Lens	146
Animal models of cataract.....	146
Biology and biochemistry of lens aging and cataractogenesis.....	150
Creating the lens-formation and function.....	154
Lens optics/biomechanics.....	158
Lens physiology and channel proteins.....	163
Lens signal transduction pathways.....	167
Omic changes in the lens.....	171
Posterior capsule opacification.....	176
The genetics of cataracts.....	180
Myopia	185
Genomics, ionic and neurovascular implications for myopia development.....	185
Retinal signals driving eye growth regulation.....	189
Scleral and choroidal mechanisms underlying myopia, new biomarkers and ideas for intervention.....	194
The International Myopia Institute: Global epidemiological trends in myopia and exploration of regional differences.....	198
Ocular Imaging	202
Advanced imaging and clinical applications.....	202
Advances in vascular imaging.....	206
Clinical applications of adaptive optics retinal imaging.....	210
Developments in fluorescence-based imaging techniques.....	214
Imaging for vision restoration.....	217
Light meets tissue – new aspects for quantitative biomechanical imaging in ophthalmology.....	220
Molecular imaging of the retina.....	225
Optoretinography.....	228
Progress in small animal ocular imaging.....	233
Retinal imaging in diabetic retinopathy - what is the latest?.....	237
Retinal pathological and imaging features in Alzheimer's disease.....	241
Understanding the functional impacts of fixation on the eye-brain connection.....	245
Ocular Immunology	249
Host and microbe interactions in corneal infection.....	249
Impact of hypoxia, oxygenation, and oxidative stress on ocular inflammation and wound healing.....	253
Infection versus autoimmunity in uveitis.....	257
Microbial effects on host response to ocular infections.....	261
Ocular immune mechanisms and infection.....	265
Ocular infection and inflammation: innovations from bench to bedside.....	269
Retinal inflammation: beyond macrophages and microglia.....	272
Tackling corneal infection and inflammation during microbial keratitis.....	276

Ocular Physiology, Pharmacology and Therapeutics	281
Advancements in precision medicine: unveiling the future of personalized healthcare.....	281
Ion channels in the eye: new roles, pathologies and therapeutic approaches.....	285
ISER-AOPT joint session on ocular pharmacology and therapeutics.....	289
Mechanistic insight and treatment strategies for incomplete responses to anti-VEGF therapy in neovascular AMD.....	293
Novel medical technologies for eye diseases.....	299
Ocular drug delivery – from bench to bedside.....	303
Ocular fibrosis mechanism and therapeutic development.....	307
Optic neuropathies and optic neuritis - new concepts of pathology and therapeutics approaches.....	312
Retinal function, diagnosis, and potential therapeutics in ocular and non-ocular diseases.....	316
Small heat shock proteins as therapeutics for eye diseases.....	320
Therapeutic strategies for ocular diseases.....	325
Topical ocular drug delivery to protect retinal neurons.....	328
Ophthalmic Genetics/Genomics	333
Epigenomics and non-coding variation.....	333
Genetic therapies for inherited retinal diseases.....	337
Global eye genetics consortium - genetic studies in pan-America.....	340
New technologies for discovery and diagnosis.....	344
OMICS approaches to understand complex disease.....	348
Retinal degenerations: genes, genomes, and treatments.....	351
RNAs and inherited ocular diseases.....	355
Retinal Cell Biology	360
Animal models in vision research.....	360
Cell biology of photoreceptors.....	364
Cellular and molecular aging in the retina.....	368
Cellular mechanisms of visual system development and their impact on disease.....	372
Cellular plasticity and regeneration.....	377
Comparative analysis of Muller glia-dependent retinal regeneration.....	381
Development of regionalization and connectivity in the visual system. Therapeutic implications.....	385
Insights into retinal development and disease.....	389
Iron and retinopathy of prematurity.....	392
Lipids and lipid-soluble molecules in retinal health and disease.....	397
Retinal connectomics / volumeEM.....	401
The retinal powerhouse: unravelling the metabolic mysteries of the retina.....	405

Retinal Degeneration

Conclusion

RXR-based therapy shows promise for the treatment of diabetes. Not only could it lower hyperglycemia effectively for diabetic patients, but it could also balance retinal lipid metabolism and reduce anti-inflammatory cytokine expression resulting in the slowing of the progression of DR.

Abstract ID: 408

Retinoid X receptors (RXR): Potential therapeutic targets in retina neurodegenerative diseases

Section: Retinal Degeneration

[Olga Lorena German](#)¹

¹*Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB); Depto. de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-CONICET, Bahía Blanca, Argentina*

Retinal neurodegenerative diseases share the death of photoreceptors (PR) as a common final step and still now lack effective treatments. Oxidative stress, degeneration or altered functionality of the retinal pigment epithelium (RPE) cells and inflammatory processes involving immunomodulatory cell types such as these RPE cells or Müller glial cells (MGCs) also play pivotal roles. Current therapeutic strategies aim to identify factors and signaling pathways to prevent neuronal death, modulate inflammation, and promote neuronal regeneration. Retinoid X receptors (RXRs), nuclear receptors governing multiple cellular functions, have attracted attention for their potential therapeutic efficacy. Since their roles in the retina are scarcely known, we investigated whether RXRs might prevent retina cell death and control inflammation.

In *in vitro* models of retinal degeneration induced by oxidative damage or BMAA, a cyanotoxin linked to retinal neurotoxicity, we demonstrated that RXR activation promoted neuronal survival and protected RPE cells from cell death, preventing reactive oxygen species (ROS) formation and loss of mitochondrial function. In neuro-glial cultures from retinas of *rd1* mouse, a model of Retinitis Pigmentosa, we evidenced that RXR activation enhanced the survival of *rd1* PR, preserving mitochondrial function, simultaneously decreasing MGC reactivity and promoting an anti-inflammatory environment, supporting a novel protective effect of RXR activation on *rd1* PR. To expand comprehension of the impact of RXR activation in immune response modulation in retina neurodegeneration, we studied whether this activation affected the immune and antiviral drug-response. We demonstrated that RXR agonists reduced the expression of proinflammatory cytokines induced by H₂O₂ (IL-6 and TNF α) and BMAA (COX-2), while promoting anti-inflammatory cytokine expression (IL-10 and TGF β). Moreover, RXR activation may modulate the response to HSV-1 viral infection in retinal cells.

Overall, our results suggest that activation of RXRs protects retina cell types from multiple injuries by acting, at least on a shared point in death pathways, such as ROS generation and mitochondrial dysfunction, while also promoting an anti-inflammatory response and modulating viral infection dynamics, offering novel insights for ocular therapeutic drug development.

Funding Sources: ANPCYT, CONICET, UNS, Fiorini and Roemmers Foundations (Argentina).
